The Plane That Almost Never Was

In 1981, the U.S. Air Force awarded Northrop a contract to build what would become the B-2 Spirit stealth bomber. The original program of record called for 132 aircraft. The plane was extraordinary. It was genuinely invisible to radar, capable of striking anywhere on earth without refueling. This was a weapons system that redefined what air power meant and the technology actually worked exactly as advertised.

Then the Cold War ended, and Congress looked at the price tag. By 1997, the program had been cut to 21 aircraft. Each one cost roughly $2.1 billion. The Air Force got a small fleet of the most capable bomber ever built, and Northrop got a program that never scaled to its intended size.

The lesson that great technology and great economics are two different things got filed away.

Now the Air Force is doing it again. The B-21 Raider, Northrop's next-generation stealth bomber, is in low-rate initial production, with 21 aircraft ordered across five lots. Congress approved $4.5 billion to accelerate production capacity.

The Air Force has agreed to increase manufacturing capability by roughly 25 percent. The program of record is a minimum of 100 aircraft, although some officials want 145 or more. Northrop CEO Kathy Warden said in January that the company expects to finalize the B-21 acceleration contract by the end of March. The question investors face today is the same one the market faced in 1981.

The technology is real. But what does that actually translate to in earnings, and when?

What the Company Does

Northrop Grumman is an aerospace and defense technology company operating through four segments. Aeronautics Systems is the fastest-growing right now. It builds the B-21 bomber, the Global Hawk unmanned surveillance aircraft, and provides F-35 airframe components to Lockheed.

Defense Systems handles tactical weapons, missile defense solutions, and solid rocket motors.

Mission Systems provides the radars, electronic warfare systems, command and control, and intelligence-processing technology that modern warfare depends on.

Space Systems builds satellites, missile defense interceptors, and spacecraft systems.

The company reported full-year 2025 sales of $42 billion, up about 2% organically, with Q4 accelerating sharply to 10% growth as the Aeronautics segment shipped against its backlog.

Adjusted EPS for the full year was $26.34 and free cash flow reached $3.3 billion, up 26% year over year.

In terms of outlook, the company holds a record backlog of $95.7 billion, which is up 4.6% year over year. That includes all four segments and represents more than two years of forward revenue coverage at current guidance levels.

The Investment Thesis

The case for Northrop rests on three things that compound together over time, and the first one is already underway.

First in my book is the B-21 inflection. Northrop has been investing heavily in the B-21 program for years at below-market-rate contracts structured to win the business. The company took a $477 million process-change charge in 2025 just to enable a higher production rate.

That kind of upfront loss is how defense primes buy long-cycle programs. The strategy is to eat the early losses, then ride the sustainment and production margin improvement for decades. CEO Kathy Warden has said explicitly that B-21 could exceed 10% of total revenue as production accelerates, and that the company expects "better profitability and cash flow" as the program matures.

With first operational delivery to Ellsworth Air Force Base targeted for 2027 and $4.5 billion in dedicated Air Force expansion funding now in play, the transition from loss-generating development program to margin-generating production program is genuinely starting.

Second is the nuclear triad monopoly. Northrop is the only company that builds both a penetrating nuclear bomber (B-21) and the ground-based ICBM that replaces Minuteman III (Sentinel). That is a structural position with no near-term competitive alternative.

The Sentinel program has faced cost overruns and a Nunn-McCurdy breach, and production won't begin for several years. But the Air Force expects a new Milestone B decision by end of 2026 and a first test launch in 2027. When Sentinel does enter production, Northrop's revenue from these two programs alone could represent a meaningful portion of total sales for the better part of a decade.

You simply cannot replicate this position.

Third and perhaps the biggest near term catalyst is international demand and the geopolitical environment. Northrop's international sales grew 20% in 2025. The US-Iran conflict that broke crude oil above $90 last week and the ongoing Ukraine conflict are not headwinds for a company selling stealth bombers, missile defense systems, and surveillance aircraft.

The Trump administration's proposed FY2027 defense budget of $1.5 trillion, referenced directly by Northrop management on the January earnings call, is the backdrop against which every Northrop contract negotiation now takes place.

Competition and Macro Context

Northrop's competitive position is unusual in defense because it genuinely has no direct competitor on its two flagship programs.

Nobody else builds the B-21. Nobody else is building the Sentinel. Lockheed Martin and Boeing are both out of the strategic bomber business after the B-21 competition. On solid rocket motors, which is a Defense Systems product that underpins hypersonics, missiles, and space launch, Northrop has invested significantly to expand domestic production capacity as the Pentagon pushes to reduce supply chain concentration risk.

The macro environment is unambiguously supportive for defense spending.

The wrinkle is that Northrop's 2026 guidance for mid-single-digit revenue growth was actually below analyst consensus estimates of $43.98 billion at the high end. Adjusted EPS guidance of $27.40-$27.90 came in below the Street's $28.78.

That is either a management team being conservative or signaling execution caution. For a stock trading near all-time highs, conservative guidance from a company with real program execution risk is worth taking seriously.

Valuation - Cheap, Fair, or Expensive?

At $735 per share as of March 11, Northrop trades at roughly 26.7x the midpoint of its 2026 adjusted EPS guidance of $27.65.

That is a notable premium for a company guiding to roughly 5% EPS growth in the current year. The EV/FCF multiple sits near 36x which is elevated, and reflective of a market pricing in substantial future earnings improvement from B-21 scaling rather than current year results.

The average analyst price target is $724, roughly 1.5% below the current price. The stock has run 61% over the past year, from a 52-week low of $450 to near its all-time high of $774.

There is a coherent bull case for a higher multiple.

The B-21 program is an annuity that accelerates from here, Sentinel adds another decade of defense revenue, and the company has a beta near zero in a volatile market. The honest assessment is that NOC is trading at a premium to its near-term earnings power on the expectation of a production ramp that is still being contracted. I want to see the B-21 acceleration deal signed and the Sentinel Milestone B achieved before I'm comfortable going all in 27x for mid-single-digit growth, but I am still adding and building my position.

What Could Go Wrong

The worst case B-2 scenario is the risk that nobody who is long NOC wants to think about.

The original B-2 program called for 132 aircraft and ended at 21. The B-21's program of record is 100 aircraft minimum, but Congress has already trimmed $620 million from procurement in the FY2026 base budget while adding R&D funding - a move that signals some unease about cost trajectory.

If geopolitical conditions change or budget pressure intensifies, production could be stretched or capped below current projections. That outcome would leave Northrop having absorbed billions in upfront investment for a program that never reaches full-rate production economics.

The Sentinel cost overrun is an ongoing liability. The program has already triggered a Nunn-McCurdy breach and been restructured once. Production is still years away.

Until Milestone B is achieved and a credible cost baseline is established, the program carries budget risk that could force additional scope changes. Northrop has said Sentinel won't contribute meaningfully to revenue for several years regardless, but the liability exposure from further overruns is real.

Rare earth supply chain exposure is an emerging issue that will be monitored more closely in the coming year. Multiple recent reports note that Northrop is overhauling its supply chain to comply with new Pentagon rules banning Chinese-origin rare earth magnet materials. This creates near-term cost and timing pressure on programs that depend on these components, including defense electronics across Mission Systems and Space Systems.

Finally, the book-to-bill ratio for full-year 2025 was precisely 1.0. This means that orders exactly matched deliveries. That is not a red flag, but it is not the 1.3x or 1.5x that signals accelerating demand. The average of the last 5 years is still above 1.1, which is strong.

For a stock priced on future growth, flat order momentum in a year of rising defense budgets is at minimum worth watching at Q1 2026 earnings on April 21.

My Take

I believe the Northrop Grumman franchise is genuinely excellent. The B-21 will eventually be a margin engine. The nuclear triad position is not replicable on any reasonable timeline. The management team has been transparent about program execution and conservative in guidance, which is the right posture when you have two headline programs under active restructuring.

The stock at $735 is a different conversation from the stock at $450 where it was twelve months ago. A 61% move has pulled a lot of the B-21 narrative forward into the current price before the earnings power has arrived.

I'm not selling NOC because the long-term structural position is too strong, and I am still building my position. For investors this is a buy, or hold for those already with an established position, with a watchful eye on the B-21 acceleration contract announcement expected by end of March, and the Q1 2026 book-to-bill ratio in late April.

Those two data points will tell you whether the 2027-2028 earnings acceleration is on track or has slipped.

The Earnout Investor provides analysis and research but DOES NOT provide individual financial advice. Jamie Dejter may have a position in some of the stocks mentioned. All content is for informational purposes only. The Earnout Investor is not a registered investment, legal, or tax advisor, or a broker/dealer. Trading any asset involves risk and could result in significant capital losses. Please, do your own research before acquiring stocks.